Your post is thought provoking and I see how some people might view it this way. My guess, though, is that Amarin's lawyers will go out of their way to say that what they're griping about regarding the label and Hikma's actions does not stretch the limits of the law or take anything beyond where the GSK-Teva case ended up. Because Hikma is screaming that Amarin is trying to rewrite the rules, exaggerate the law and eliminate the ability of generics to get into these markets at all. They know that argument is well received by Congress and all the states that would like all drugs to be generic all the time. And they know that if they make it sound like the Amarin case is trying to stretch the law to new limits and ruin generics, then they might find receptive ears on the courts as well. So Amarin will stay in its lane here. I'm not a lawyer but I've watched thousands of court cases proceed over the years.
Market Data 
Markets 
AI
